Why the study?
Does PON1 polymorphism affect the risk of major cardiovascular events in AMI patients treated with clopidogrel?
Does PON1 polymorphism affect the risk of major cardiovascular events in AMI patients treated with clopidogrel?
Unlike CYP2C19, PON1 polymorphism is not a major pharmacogenetic determinant of clinical outcomes in clopidogrel-treated AMI patients.
Answers are grounded in this paper and cite their sources.
PON1 testing should not guide clopidogrel use in AMI; reinforces CYP2C19 focus while leaving other genetic determinants open.
Paraoxonase-1 (PON1) Q192R polymorphism was recently suggested to determine per se clopidogrel response on major cardiovascular events (MACEs). We assessed the impact of PON1, CYP2C19, and ABCB1 polymorphisms on MACE in clopidogrel-treated acute myocardial infarction (AMI) patients (N = 2,210), including those undergoing percutaneous coronary intervention (PCI) (n = 1,538). PON1 polymorphism was not associated with increased risk of in-hospital death and MACEs at 1 year (adjusted hazard ratio (HR) 1.03, 95% confidence interval (CI) 0.66-1.61 and adjusted HR 0.77, 95% CI 0.42-1.41 for QQ versus RR in all and PCI patients, respectively). The presence of two CYP2C19 loss-of-function (LOF) alleles was associated with the risk of in-hospital death and MACEs at 1 year in the overall population (adjusted odds ratio (OR) 3.67, 95% CI 1.05-12.80 and adjusted HR 1.96, 95% CI 1.08-3.54) and in PCI patients (adjusted OR 6.87, 95% CI 2.52-18.72 and adjusted HR 3.06, 95% CI 1.47-6.41). Unlike CYP2C19 polymorphism, PON1 (Q192R) polymorphism is not a major pharmacogenetic contributor of clinical response to clopidogrel in AMI patients.
No takes yet. Share an insight, caveat, or question.
Simon et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: